Bill Meury says his company now has blood, cancer, and immune treatments to replace sales from its top-selling drug, Jakafi, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Incyte Corporation INCY announced pooled analysis of five-year data from two phase III studies – COMFORT-I and COMFORT-II – on Jakafi, which support previously published overall survival (OS) ...

Incyte's valuation still appears attractive if pipeline execution continues and analysts eventually raise long-term ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion. Jakafi (ruxolitinib) net product revenues ...

Transparency is our policy. Learn how it impacts everything we do Investing Terms and Definitions ...

Two studies showed that Jakafi has high response rates with patients with GVHD, making the FDA give the drug a breakthrough therapy designation. Jakafi (ruxolitinib) was given a breakthrough therapy ...

Patients with myelofibrosis and anemia showed similar spleen size and symptom improvements as the overall JUMP study cohort when treated with ESAs or danazol and Jakafi. The JUMP trial, a phase 3b ...

We’re maintaining our $88 fair value estimate for Incyte INCY following first-quarter results that were relatively in line with our expectations, despite sales for both hematology drug Jakafi (up 7% ...

Incyte Corporation's (NASDAQ:INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. Analysts had estimated $0.87. Q2 revenues increased by 25% Y/Y to $954.61 million, beating the ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (NAS: INCY) announced today that the U.S. Food and Drug Administration (FDA) has updated prescribing information for Jakafi® (ruxolitinib) to ...

- GVHD is a serious and common complication of allogeneic stem cell transplants with no widely approved treatment options for patients who do not respond to steroids WILMINGTON, Del.--(BUSINESS WIRE)- ...